Canlyniadau Chwilio - Jueliger, Simone

Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma gan Ferrari, Nicola, Ward, George, Gewinner, Christina, Davis, Matthew P., Jueliger, Simone, Saini, Harpreet, Munck, Joanne, Smyth, Tomoko, Ferraldeschi, Roberta, Keer, Harold, Lyons, John, Sims, Martin J.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma gan Jueliger, Simone, Lyons, John, Cannito, Sara, Pata, Illar, Pata, Pille, Shkolnaya, Marianna, Lo Re, Oriana, Peyrou, Marion, Villarroya, Francesc, Pazienza, Valerio, Rappa, Francesca, Cappello, Francesco, Azab, Mohammad, Taverna, Pietro, Vinciguerra, Manlio

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A Phase 1 Clinical Trial of Guadecitabine and Carboplatin In Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic And Pharmacodynamic Analyses gan Matei, Daniela, Ghamande, Sharad, Roman, Lynda, Secord, Angeles Alvarez, Nemunaitis, John, Markham, Merry Jennifer, Nephew, Kenneth P., Jueliger, Simone, Oganesian, Aram, Naim, Sue, Su, Xiang Yao, Keer, Harold, Azab, Mohammad, Fleming, Gini F

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing gan Riccadonna, Cristina, Yacoub Maroun, Céline, Vuillefroy de Silly, Romain, Boehler, Margaux, Calvo Tardón, Marta, Jueliger, Simone, Taverna, Pietro, Barba, Leticia, Marinari, Eliana, Pellegatta, Serena, Bassoy, Esen Yonca, Martinvalet, Denis, Dietrich, Pierre-Yves, Walker, Paul R.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

First-in-human study of AT13148, a dual ROCK-AKT inhibitor in patients with solid tumors gan McLeod, Robert, Kumar, Rajiv, Papadatos-Pastos, Dionysis, Mateo, Joaquin, Brown, Jessica S, Garces, Alvaro H Ingles, Ruddle, Ruth, Decordova, Shaun, Jueliger, Simone, Ferraldeschi, Roberta, Maiques, Oscar, Sanz-Moreno, Victoria, Jones, Paul, Traub, Stephanie, Halbert, Gavin, Mellor, Sarah, Swales, Karen E, Raynaud, Florence I, Garrett, Michelle D, Banerji, Udai

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure gan Sébert, Marie, Renneville, Aline, Bally, Cécile, Peterlin, Pierre, Beyne-Rauzy, Odile, Legros, Laurence, Gourin, Marie-Pierre, Sanhes, Laurence, Wattel, Eric, Gyan, Emmanuel, Park, Sophie, Stamatoullas, Aspasia, Banos, Anne, Laribi, Kamel, Jueliger, Simone, Bevan, Luke, Chermat, Fatiha, Sapena, Rosa, Nibourel, Olivier, Chaffaut, Cendrine, Chevret, Sylvie, Preudhomme, Claude, Adès, Lionel, Fenaux, Pierre

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer gan Oza, Amit, Matulonis, Ursula, Alvarez Secord, Angeles, Roman, Lynda, Blagden, Sarah, Banerjee, Susana, Nemunaitis, John, McGuire, William, Ghamande, Sharad, Birrer, Michael, Fleming, Gini F, Jennifer Markham, Merry, Hirte, Hal, Provencher, Diane, Basu, Bristi, Kristeleit, Rebecca, Armstrong, Deborah, Schwartz, Benjamin, Braly, Patricia, Hall, Geoffrey, Nephew, Kenneth P., Jueliger, Simone, Oganesian, Aram, Naim, Sue, Hao, Yong, Keer, Harold, Azab, Mohammad, Matei, Daniela

Cael y testun llawn Cael y testun llawn Cael y testun llawn